<DOC>
	<DOCNO>NCT01935518</DOCNO>
	<brief_summary>This study examine whether fasudil effective safe treat patient amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>A Clinical Trial Safety Efficacy Fasudil Subjects With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>This open label , single center clinical study placebo historical research control . 10 patient enrol study . The basic treatment riluzole , 50mg twice day . For procedure , patient take fasudil treatment 14 day ( 30mg twice day , intravenous ) . 3 month later , patient repeat fasudil treatment . All patient follow 6 month . The primary outcome decline rate ALSFRS-R . The secondary outcome survival time , endpoint time ( death , tracheotomy continuous ventilator-dependent ) , force vital capacity ( FVC ) , short form health survey ( SF-36 ) , evaluation cognitive function ( verbal fluency Frontal Behavioral Inventory Scale ) safety .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Fasudil</mesh_term>
	<mesh_term>1- ( 5-Isoquinolinesulfonyl ) -2-Methylpiperazine</mesh_term>
	<criteria>Clinical diagnosis laboratorysupported probable , probable , definite ALS Age : 1870 year Disease duration : 336 month Forced vital capacity : least 60 % predict ALSFRSR : least 30 , respiratory item : least 10 Decline ALSFRSR last 3 month enrollment : 18 Must take riluzole , stable dose least 30 day prior baseline visit serious side effect . They must continue riluzole treatment least 6 month enrollment . Patients childbearing potential must use effective method birth control Willing able give inform consent Familial ALS Pregnant nursing woman Patients tracheotomy continuous ventilatordependent ( time noninvasive ventilator 22 hour per day 7 consecutive day . ) After percutaneous endoscopic gastrostomy Alanine Transaminase ( ALT ) Aspartate Transaminase ( AST ) : least 3 time upper limit normal Abnormal creatinine urea nitrogen Severe cardiac disease , pulmonary disease , hematic disease , autoimmune disease , mental disease , dementia substance abuse History malignancy History intracranial hemorrhage History severe bleed digestive tract , lung , nose skin Allergic fasudil Participating clinical study use investigational drug present</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>